摘要
目的探讨表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效。方法根据治疗方法的不同将150例经基因测序均为EGFR突变阳性的Ⅲb或Ⅳ期NSCLC患者分为观察组和对照组,每组75例。对照组接受EGFR-TKI治疗,观察组在对照组的基础上联合化疗药物进行治疗。比较两组患者的临床疗效、无进展生存期(PFS)和不良反应发生情况。结果观察组患者的客观有效率(ORR)和疾病控制率(DCR)均高于对照组患者(P﹤0.05)。观察组患者的中位PFS为13.5个月(95%CI:11.621~15.349),长于对照组患者的9个月(95%CI:7.903~10.889)(P﹤0.05)。两组患者的不良反应发生情况比较,差异无统计学意义(P﹥0.05)。两组患者均未发生4级严重不良反应,且观察组并未出现3级皮疹和骨髓抑制的不良反应。结论EGFR-TKI联合化疗治疗晚期NSCLC患者临床疗效显著,可延长患者的PFS,且未增加不良反应。
Objective To investigate the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor,(EGFR-TKI)combined with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Method 150 stage Ⅲb or Ⅳ NSCLC patients with positive EGFR mutationby gene sequencing were divided into observation group(n=75,treated with EGFR-TKI+chemotherapy)and control group(n=75,treated with EGFR-TKI).The clinical efficacy,progression-free survival(PFS)and adverse reactions were compared between the two groups.Result The objective effective rate(ORR)and disease control rate(DCR)in the observation group were significantly higher than those in the control group(P<0.05).The median PFS of the observation group and the control group was 13.5 months(95%CI:11.621-15.349)and 9 months(95%CI:7.903-10.889),respectively(P<0.05).There were no significant differences for adverse reactions between the two groups(P>0.05).There were no grade 4 adverse reactions in both groups,and there were no grade 3 rashes and myelosuppression in the observation group.Conclusion EGFR-TKI combined with chemotherapy is effective in the treatment of patients with advanced NSCLC,which can effectively prolong PFS and reduce the adverse reactions.
作者
王鹏
董玉
丁海霞
董卫侠
王冠杰
WANG Peng;DONG Yu;DING Haixia;DONG Weixia;WANG Guanjie(Departmentof Respiratory and Critical Care Medicine,Xi’an Central Hospital,Xi’an 710001,Shaanxi,China)
出处
《癌症进展》
2020年第24期2539-2542,共4页
Oncology Progress
关键词
表皮生长因子受体-酪氨酸激酶抑制剂
化疗
非小细胞肺癌
无进展生存期
安全性
epidermal growth factor receptor-tyrosine kinase inhibitor
chemotherapy
non-small cell lung cancer
progression free survival
safety
